News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Singapore offices install soil-free farms to fix RTO culture
Grobrix turns office walls into edible gardens that employees maintain together, betting participation beats passive perks for workplace engagement.
Oregon Restaurant Pays $215K for Overtime and Tip Pool Violations
Federal investigation found Taste of India 1 denied overtime to 19 workers and misused tip pools, resulting in $200K back wages plus penalties.
Ex-BigLaw lawyer releases open source Harvey clone
Former Latham attorney Will Chen launched Mike, an open source legal AI platform that replicates Harvey's core functions and runs locally on firm infrastructure.
Sleep data inconsistency undermines AI health predictions
Consumer sleep trackers produce wildly different readings for the same person, creating safety risks as AI systems scale decisions on unreliable inputs.
Healthcare IT News posts conference ads as rural funding story
The source contains only promotional material for HIMSS conferences with no substantive content about rural care networks or federal funding.
My Dr Now hits 75 clinics mixing virtual and home care
Southwest primary care network reports 15% annual growth and 92% patient adherence by combining telehealth, clinic visits, and home services in one system.
QIAGEN pushes curated data over raw scale for AI drug repurposing
Sponsored content argues expert-curated knowledge graphs beat bigger datasets for finding oncology repurposing opportunities.
UCB pays $2.2B for Candid's China-licensed bispecifics portfolio
Belgian pharma bets on antibody drugs from Chinese biotechs to enter the autoimmune bispecifics market.
Latus raises $97M for lower-dose gene therapies beyond rare disease
Biotech targets Huntington's and Batten disease with viral capsids designed for efficient delivery at reduced doses and manufacturing costs.
Windward Bio raises $165M for China-licensed asthma drug Phase 3
Swiss biotech secures funding to advance two experimental medicines from Chinese partners into late-stage trials.
Biotech startups pivot to licensing Chinese assets over R&D
Small teams are raising large funding rounds to in-license Chinese biotech assets rather than build new platforms from scratch.
Celcuity breast cancer drug hits Phase 3 endpoints
Two gedatolisib regimens succeeded in PIK3CA mutant patients, building on prior trial wins for the experimental treatment.